Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102475 | 0.79 | MAPT (0.36) | GABRA1GABRB2MAPT | |
| SCHEMBL12320858 | 0.76 | GABRA1 (0.36) | GABRA1GABRB2MAPTDPP4 | |
| SCHEMBL6650753 | 0.75 | PYCR1 (0.43) | GABRA1GABRB2MAPTTBXA2RPTGER1 | |
| SCHEMBL12102411 | 0.73 | ACE2 (0.41) | MAPT | |
| SCHEMBL2662565 | 0.73 | GABRA1 (0.47) | GABRA1GABRB2 | |
| SCHEMBL8252272 | 0.72 | PYCR1 (0.46) | GABRA1GABRB2DPP4 | |
| SCHEMBL11462319 | 0.72 | PYCR1 (0.46) | GABRA1GABRB2MAPT | |
| SCHEMBL12034410 | 0.71 | ALDH1A1 (0.42) | MAPTPTGER1 | |
| SCHEMBL12204983 | 0.71 | ALOX15 (0.39) | GABRA1GABRB2MAPTTBXA2RPTGER1 | |
| SCHEMBL20562690 | 0.70 | GABRA1 (0.35) | GABRA1GABRB2MAPTTBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | GABRA1 1287/4885GABRB2 536/4885MAPT 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.